Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

9.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.5K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

11.0K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.0K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

5.8K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
5.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair-deficient Metastatic Castration-resistant Prostate Cancer.

European urology oncology·2025
Same author

Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024
Same author

Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: Analysis of the phase 3 VISION trial.

Cancer·2024
Same author

Corrigendum to "Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial" [Eur. Eurol. 84(2) (2023) 156-163].

European urology·2024
Same author

BATF-dependent Th17 cells act through the IL-23R pathway to promote prostate adenocarcinoma initiation and progression.

Journal of the National Cancer Institute·2024
Same author

Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1.

JU open plus·2024
Same journal

Toward Interpretable Machine Learning Models for Grading Prostate Cancer: A Multicenter Development and Validation Study.

Clinical genitourinary cancer·2026
Same journal

Primary Mediastinal Seminoma: Clinical Characteristics and Outcomes.

Clinical genitourinary cancer·2026
Same journal

Time to Treatment Initiation and Survival in Patients With Muscle-Invasive Bladder Cancer (MIBC).

Clinical genitourinary cancer·2026
Same journal

PROTEUS and the Perioperative Intensification Era in High-risk Prostate Cancer.

Clinical genitourinary cancer·2026
Same journal

Circulating Tumor DNA After Radical Cystectomy as a Marker of Minimal Residual Disease in Muscle-Invasive Bladder Cancer: A Literature Review.

Clinical genitourinary cancer·2026
Same journal

Trophoblastic-Differentiated Urothelial Carcinoma: Real-World Sequencing and Clinical Implications.

Clinical genitourinary cancer·2026
See all related articles

Related Experiment Video

Updated: Jan 2, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K

TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer.

Lynne Chapman1, Elisa M Ledet2, Pedro C Barata2

  • 1Tulane University School of Medicine, New Orleans, LA.

Clinical Genitourinary Cancer
|December 12, 2019
PubMed
Summary
This summary is machine-generated.

Gain-of-function TP53 mutations in prostate cancer are linked to prior abiraterone/enzalutamide therapy. This finding may help categorize metastatic castration-resistant prostate cancer for targeted treatments.

Keywords:
AbirateroneEnzalutamideTP53ctDNAmCRPC

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.1K
Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
12:09

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

6

Related Experiment Videos

Last Updated: Jan 2, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.1K
Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
12:09

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

6

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Circulating tumor DNA (ctDNA) analysis via liquid biopsy offers genomic insights into prostate cancer treatment response.
  • Characterizing TP53 mutations and their correlation with treatment history is crucial for understanding disease progression.

Purpose of the Study:

  • To investigate the characteristics of TP53 mutations in patients with metastatic castration-resistant prostate cancer.
  • To analyze the association between TP53 mutation status and prior therapeutic interventions.

Main Methods:

  • 143 metastatic castration-resistant prostate cancer patients underwent ctDNA sequencing (Guardant360).
  • TP53 mutations were identified and classified as gain-of-function (GOF) or not GOF.
  • Statistical analysis (Chi-square) correlated TP53 status with prior abiraterone, enzalutamide, and docetaxel therapies.

Main Results:

  • No association was found between prior abiraterone/enzalutamide or docetaxel therapy and all TP53 mutations.
  • TP53 GOF mutations showed a positive association with prior abiraterone/enzalutamide therapy (P = .047).
  • RB1 mutations were associated with TP53 GOF mutations (P = .0036). Frequent co-alterations included AR, BRAF, EGFR, and PIK3CA.

Conclusions:

  • TP53 GOF mutations may help stratify metastatic castration-resistant prostate cancer patients into therapeutic categories.
  • An association between TP53 GOF mutations and progression during abiraterone/enzalutamide therapy was observed, warranting further investigation.